ocebo effects in fibromyalgia pain progressio

Recruiting

• Conditions: Patients with fibromyalgia (N=103) and matched healthy control participants (N=34)

• Registration Number: NL-OMON24049
• Lead Sponsor: eiden University

Brief Summary

/A

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 137

Inclusion Criteria

Participants must meet all of the following criteria:
•Female
•Age18-65
•Fluent in Dutch language (written and spoken)
•Able to give informed consent

Additionally, for patients:
•Fibromyalgia diagnosis by a rheumatologist, as reported by the patient and as verified by provision of the date, location, and provider of the diagnosis.

Exclusion Criteria

Participants will be excluded for the following criteria:
•Pregnancy or breastfeeding
•Color blindness
•Injuries/open wounds on the non-dominant hand or arm on the day of laboratory session
•Carrying a pacemaker/implanted pumps
•Having implanted metals on the non-dominant hand or arm
•Refusal/inability to remove possible artificial nails or nail polish covering the thumbnail

Specific for patients, additionally:
•A medical diagnosis other than fibromyalgia explaining the chronic pain symptoms
•Severe physical or mental co-morbidities that are not related to fibromyalgia symptoms (e.g., DSM-V diagnosis of psychosis, suicidal ideation, addiction)
•Use of painkillers different than usual dose of treatment on the day of experimentation

Specific for healthy controls, additionally:
•Chronic pain complaints =3 months in the past or present or a diagnosis of fibromyalgia
•Current pain
•Severe physical or psychiatric co-morbidities that may interfere with the study protocol (e.g., DSM-V diagnosis)
•Use of painkillers within 24 hours before the day of experimentation

Study & Design

• Study Type: Interventional
• Study Design: Not specified